These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9364054)

  • 1. Altered trafficking of mutant connexin32.
    Deschênes SM; Walcott JL; Wexler TL; Scherer SS; Fischbeck KH
    J Neurosci; 1997 Dec; 17(23):9077-84. PubMed ID: 9364054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypes of X-linked Charcot-Marie-Tooth disease and altered trafficking of mutant connexin 32 (GJB1).
    Matsuyama W; Nakagawa M; Moritoyo T; Takashima H; Umehara F; Hirata K; Suehara M; Osame M
    J Hum Genet; 2001; 46(6):307-13. PubMed ID: 11393532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular mechanisms of connexin32 mutations associated with CNS manifestations.
    Kleopa KA; Yum SW; Scherer SS
    J Neurosci Res; 2002 Jun; 68(5):522-34. PubMed ID: 12111842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ
    Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse trafficking abnormalities of connexin32 mutants causing CMTX.
    Yum SW; Kleopa KA; Shumas S; Scherer SS
    Neurobiol Dis; 2002 Oct; 11(1):43-52. PubMed ID: 12460545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant trafficking of a Leu89Pro connexin32 mutant associated with X-linked dominant Charcot-Marie-Tooth disease.
    Da Y; Wang W; Liu Z; Chen H; Di L; Previch L; Chen Z
    Neurol Res; 2016 Oct; 38(10):897-902. PubMed ID: 27367520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.
    Kyriakoudi S; Sargiannidou I; Kagiava A; Olympiou M; Kleopa KA
    Hum Mol Genet; 2017 May; 26(9):1622-1633. PubMed ID: 28334782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the gap junction protein connexin32 in the pathogenesis of X-linked Charcot-Marie-Tooth disease.
    Scherer SS; Bone LJ; Deschênes SM; Abel A; Balice-Gordon RJ; Fischbeck KH
    Novartis Found Symp; 1999; 219():175-85; discussion 185-7. PubMed ID: 10207904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in connexin 32: the molecular and biophysical bases for the X-linked form of Charcot-Marie-Tooth disease.
    Abrams CK; Oh S; Ri Y; Bargiello TA
    Brain Res Brain Res Rev; 2000 Apr; 32(1):203-14. PubMed ID: 10751671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connexin32 and X-linked Charcot-Marie-Tooth disease.
    Bone LJ; Deschênes SM; Balice-Gordon RJ; Fischbeck KH; Scherer SS
    Neurobiol Dis; 1997; 4(3-4):221-30. PubMed ID: 9361298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and cellular expression of two novel connexin32 mutations causing CMT1X.
    Kleopa KA; Zamba-Papanicolaou E; Alevra X; Nicolaou P; Georgiou DM; Hadjisavvas A; Kyriakides T; Christodoulou K
    Neurology; 2006 Feb; 66(3):396-402. PubMed ID: 16476939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal gene therapy in mouse models expressing CMT1X mutations.
    Kagiava A; Karaiskos C; Richter J; Tryfonos C; Lapathitis G; Sargiannidou I; Christodoulou C; Kleopa KA
    Hum Mol Genet; 2018 Apr; 27(8):1460-1473. PubMed ID: 29462293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connexin channels in Schwann cells and the development of the X-linked form of Charcot-Marie-Tooth disease.
    Ressot C; Bruzzone R
    Brain Res Brain Res Rev; 2000 Apr; 32(1):192-202. PubMed ID: 10751670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular transport, assembly, and degradation of wild-type and disease-linked mutant gap junction proteins.
    VanSlyke JK; Deschenes SM; Musil LS
    Mol Biol Cell; 2000 Jun; 11(6):1933-46. PubMed ID: 10848620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenylation-defective human connexin32 mutants are normally localized and function equivalently to wild-type connexin32 in myelinating Schwann cells.
    Huang Y; Sirkowski EE; Stickney JT; Scherer SS
    J Neurosci; 2005 Aug; 25(31):7111-20. PubMed ID: 16079393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of connexin-32 mutants associated with X-linked dominant Charcot-Marie-Tooth disease.
    Wang HL; Chang WT; Yeh TH; Wu T; Chen MS; Wu CY
    Neurobiol Dis; 2004 Mar; 15(2):361-70. PubMed ID: 15006706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.
    Scherer SS; Xu YT; Messing A; Willecke K; Fischbeck KH; Jeng LJ
    J Neurosci; 2005 Feb; 25(6):1550-9. PubMed ID: 15703409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of connexin32 in Charcot-Marie-Tooth disease type X interfere with cell-to-cell communication but not cell proliferation and myelin-specific gene expression.
    Yoshimura T; Satake M; Ohnishi A; Tsutsumi Y; Fujikura Y
    J Neurosci Res; 1998 Jan; 51(2):154-61. PubMed ID: 9469569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies in transgenic mice indicate a loss of connexin32 function in X-linked Charcot-Marie-Tooth disease.
    Abel A; Bone LJ; Messing A; Scherer SS; Fischbeck KH
    J Neuropathol Exp Neurol; 1999 Jul; 58(7):702-10. PubMed ID: 10411340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
    Kleopa KA; Scherer SS
    Neuromolecular Med; 2006; 8(1-2):107-22. PubMed ID: 16775370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.